T2 Biosystems to Host Business Update Call on October 10, 2024

TTOO 10.08.2024

Full Press ReleaseSEC FilingsOur TTOO Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
  • 12.20.2024 - T2Bacteria for the Diagnosis of Culture-Negative Infective Endocarditis

Recent Filings

  • 01.21.2025 - DEF 14A Other definitive proxy statements
  • 01.17.2025 - 8-K Current report
  • 01.08.2025 - PRE 14A Other preliminary proxy statements

LEXINGTON, Mass.,Oct. 08, 2024(GLOBE NEWSWIRE) --T2 Biosystems, Inc.(NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at4:30pm ETonThursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team atir@T2Biosystems.com.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event atwww.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 702677, approximately ten to five minutes prior to the start time.

AboutT2 BiosystemsT2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology and include the T2Dx®Instrument, the T2Bacteria®Panel, the T2Candida®Panel, the T2Resistance®Panel, and the T2BiothreatTM Panel. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the T2LymeTM Panel, and the expended T2Candida Panel to add the detection ofCandida auris. For more information, please visitwww.t2biosystems.com.

Investor Contact:Philip Trip Taylor,Gilmartin Groupir@T2Biosystems.com415-937-5406

Primary Logo

Source: T2 Biosystems, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com